Delivering on our promise to be a global leader in the Beauty and Wellness Industry, NW Tech Capital (www.NWTTCapital.com ) (OTC: NWTT) and TROPICSLAB is pleased to announce that award winning Nollywood celebrity Stella Damasus, has joined us, as lead Consultant for talent acquisition of the Company’s Beauty and Wellness division in its African expedition.
Stella Damasus is a highly celebrated Nigerian celebrity (actor/singer) with a refined skill and several years of experience and expertise, traveling and empowering celebrities across Africa.
She is tasked with the responsibility to expand the company’s tentacles by acquiring the best talents to fulfill our vision of establishing a flurry of high-end celebrity cosmetic brands across Africa.
NW Tech Capital is a publicly traded diversified holding company (OTC: NWTT) that was founded in1996, actively involved in the acquisition and investment of small, mid-size and development-stage private businesses in varied industries.
Based on Tropicslab’s clinically tested formula, over the next Five (5) years, NWTT projects to invest at least One Hundred Million Dollars ($100,000,000) in Africa, in Skincare research and development, manufacturing, distribution, marketing, to generate substantial revenue for our shareholders and to help combat skin cancer for people of color.
“Stella brings with her a wealth of experience and refined skill in talent acquisition that is almost unparalleled in today's market,” said NWTT CEO Cedric Yengo. “With her extensive connections in the industry and her acumen for strategic alliances, we believe that Stella will help us to position ourselves as the premier Beauty and Wellness Company, in the nearest future”.
According to Edith Delight CEO of Tropicslab, “The Task Force led by Stella Damasus will begin accepting applications from celebrities immediately, for the creation of high end celebrity cosmetic brands”.
Distributed by APO Group on behalf of NW TECH CAPITAL INC..
Contact:
Cedric Yengo
CEO, NW Tech Capital, Inc
info@nwttcapital.com
DISCLOSURE NOTICE:
The information contained in this release is as of August, 2022. NW Tech Capital assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information related to NW Tech Capital and Stella Damasus and a commitment to create a working relationship to engage in skincare manufacturing that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements in this release include, among other things, statements about the potential benefits of the proposed transaction, anticipated accretion and cost savings, the companies’ plans, objectives, expectations and intentions, the financial condition, results of operations and business of the proposed joint venture, the proposed joint venture’s products and potential, the anticipated impact of the consolidation of the NW Tech Capital’s skincare business from its financial statements, and the anticipated timing of closing of the transaction. Risks and uncertainties include, among other things, risks related to the satisfaction of the conditions to closing the transaction (including the failure to obtain necessary regulatory and shareholder approvals) in the anticipated timeframe or at all and the possibility that the transaction does not close; risks related to the ability to realize the anticipated benefits of the transaction, including the possibility that the expected benefits and cost savings from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; the possibility that a future separation of the joint venture may not occur; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of the announcement or the consummation of the proposed transaction on the market price of NW Tech Capital’s common stock and on NW Tech Capital’s operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed transaction; other business effects, including the effects of industry, market, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; and competitive developments.
A further description of risks and uncertainties shall be found in NWTT's Annual Report on Form 10-K for the fiscal year ending December 2022, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results,” as well as in its subsequent reports on Form 8-K, all of which shall be filed with the U.S. Securities and Exchange Commission and available at www.sec.gov.